<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585661</url>
  </required_header>
  <id_info>
    <org_study_id>15.06.MET</org_study_id>
    <nct_id>NCT02585661</nct_id>
  </id_info>
  <brief_title>Iron Bioavailability From Dairy Product</brief_title>
  <official_title>Iron Bioavailability From Fortified Dairy Product in Healthy Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determination of fractional iron absorption from dairy product fortified with 2 labelled iron&#xD;
      compounds&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single center trial will be double-blind, controlled randomized with a crossover trial.&#xD;
      One group (n=10) will start the study with the consumption of a Fe-54 salt fortified dairy&#xD;
      product, while the other group will start the study with the consumption of Fe-57 salt&#xD;
      fortified dairy product. The day after, in a cross over design, subjects will be administered&#xD;
      the alternative test product. A blood sampling will be performed 14 days after the last&#xD;
      stable isotope administration to allow the measurement of Fe stable isotope ratios and the&#xD;
      calculation of Fe absorption. The duration of the trial will be 16 days in total.&#xD;
&#xD;
      The total sample size is 20 enrolled subjects. Patients will be healthy females aged 18-40&#xD;
      years old&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the isotopic ratio of iron in blood at week 2</measure>
    <time_frame>14 days after the last stable isotope administration</time_frame>
    <description>The change in the isotopic ratio of iron will be measured after the administration of test meal including iron isotopes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of plasma ferritin as biomarker of Fe status</measure>
    <time_frame>On the 1st day of the stable isotope administration</time_frame>
    <description>The plasma ferritin will be measured before the administration of test meal including iron isotopes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Dairy product + Salt 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dairy product fortified with enriched Fe-54 salt (1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dairy product + Salt 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dairy product fortified with enriched Fe-57 salt (2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dairy product fortified with enriched Fe-54 salt (1)</intervention_name>
    <description>2.5mg of Fe per 100g of product</description>
    <arm_group_label>Dairy product + Salt 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dairy product fortified with enriched Fe-57 salt (2)</intervention_name>
    <description>2.5mg of Fe per 100g of product</description>
    <arm_group_label>Dairy product + Salt 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18-40 years old,&#xD;
&#xD;
          -  Healthy, based on the medical screening visit including a blood formula and&#xD;
             biochemistry,&#xD;
&#xD;
          -  Normal BMI for age (18.5-25.0),&#xD;
&#xD;
          -  Weight less than 65 kg,&#xD;
&#xD;
          -  Having obtained informed consent prior trial entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia or polycythemia respectively evidenced,&#xD;
&#xD;
          -  Significant blood losses over the past 6 months,&#xD;
&#xD;
          -  Plasma ferritin out of 8-50 ug/L range.&#xD;
&#xD;
          -  Any infectious and inflammatory disease in the past four weeks,&#xD;
&#xD;
          -  Relevant digestive (intestinal, gastric, hepatic or pancreatic), renal, metabolic&#xD;
             disease,&#xD;
&#xD;
          -  Known food allergy,&#xD;
&#xD;
          -  Pregnancy (anamnesis) and/or lactation,&#xD;
&#xD;
          -  History of cancer within the past year,&#xD;
&#xD;
          -  Significant weight loss during the last 3 months (5% and more),&#xD;
&#xD;
          -  medication or supplement which may impact red cells count, Hb or Ht&#xD;
&#xD;
          -  Fe supplementation or perfusion in the last three months,&#xD;
&#xD;
          -  Smokers (&gt;5 cigarettes),&#xD;
&#xD;
          -  Have a high alcohol consumption (more than 2 drinks/day),&#xD;
&#xD;
          -  Consumption of illicit drugs anamnesis only,&#xD;
&#xD;
          -  Subject having a hierarchical link with the Investigator or co-investigators,&#xD;
&#xD;
          -  Subject who cannot be expected to comply with treatment or study procedure,&#xD;
&#xD;
          -  participating or having participated in another clinical trial during the past month&#xD;
             prior to the beginning of this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Beaumont</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metabolic Unit - Nestec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic Unit, Clinical Development Unit, Nestec</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

